ASSEMBLY BIOSCIENCES, INC.(ASMB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,058 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in ASMB
Events flagged as statistical outliers against ASMB's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-13
ASMB quality score jumped 15 points (27→41) on a new filing
View source filing →
ASMB Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for ASSEMBLY BIOSCIENCES, INC. (ASMB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ASMB at 41.5/100 on a 32-signal composite quality model, placing it at rank #2,058 of 2,962 stocks — the bottom half of the AI-ranked universe. ASMB scores in the top quartile across revenue growth (92.3), institutional flow (84.4). Areas of concern include earnings quality (1.3) and free cash flow (6.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 21.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ASSEMBLY BIOSCIENCES, INC. reports quarterly revenue of $13.4M, net income of $-3.9M, free cash flow of $-15.5M. Top institutional holders of ASMB by reported 13-F value include GILEAD SCIENCES, FARALLON CAPITAL MANAGEMENT, Paradigm Biocapital Advisors, based on the most recent SEC filings. ASMB trades on the Nasdaq exchange and files with the SEC under CIK 1426800. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ASMB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ASSEMBLY BIOSCIENCES, INC. directly from SEC EDGAR. ASSEMBLY BIOSCIENCES, INC.'s 13F Pro composite quality score has ranged between 9 and 42 since 2021, currently 41.5 — an improving long-term trajectory across 64 quarterly and live scoring snapshots.
Revenue
Q2 2026
$13.4M
Net Income
Q2 2026
$-3.9M
Free Cash Flow
Q2 2026
$-15.5M
ROIC
Q2 2026
-8.3%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+153.5% YoYNet Income
+84.8% YoYOperating Income
+73.3% YoYEPS (Diluted)
+83.6% YoYTotal Assets
+116.2% YoYOp. Cash Flow
+19.6% YoYFree Cash Flow
+19.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $72.3M +153.5% | $28.5M +298.2% | $7.2M | $0.00 -100.0% | $6.3M -92.1% | $79.1M |
| Net Income | $-6.1M +84.8% | $-40.2M +34.4% | $-61.2M +34.2% | $-93.1M +28.3% | $-129.9M -108.9% | $-62.2M |
| Operating Income | $-12.1M +73.3% | $-45.4M +29.7% | $-64.6M +31.3% | $-94.1M +29.1% | $-132.7M -104.8% | $-64.8M |
| EPS (Diluted) | $-0.55 +83.6% | $-3.35 +50.0% | $-6.69 +42.0% | $-11.54 -284.7% | $-3.00 | — |
| Total Assets | $257.6M +116.2% | $119.2M -12.9% | $136.8M +34.4% | $101.8M -46.7% | $191.1M -32.5% | $283.3M |
| Operating Cash Flow | $-41.1M +19.6% | $-51.1M -324.8% | $22.7M +126.9% | $-84.5M +9.6% | $-93.4M -48.3% | $-63.0M |
| Free Cash Flow | $-41.2M +19.5% | $-51.1M -327.4% | $22.5M +126.6% | $-84.6M +12.4% | $-96.5M -52.1% | $-63.4M |
Get alerted when ASMB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ASSEMBLY BIOSCIENCES, INC. including:
Top Institutional Holders of ASMB
GILEAD SCIENCES, INC.
$136.8M4,977,089 shFARALLON CAPITAL MANAGEMENT LLC
$44.1M1,604,590 shParadigm Biocapital Advisors LP
$42.7M1,553,748 shCommodore Capital LP
$38.9M1,415,000 shRA CAPITAL MANAGEMENT, L.P.
$28.0M1,020,410 shJupiter Topco LLC
$23.4M849,309 shBlackRock, Inc.
$21.1M766,819 shParkman Healthcare Partners LLC
$19.8M721,181 shVANGUARD CAPITAL MANAGEMENT LLC
$15.4M558,942 shPoint72 Asset Management, L.P.
$12.7M460,593 sh
| Fund | Value | Shares |
|---|---|---|
| GILEAD SCIENCES, INC. | $136.8M | 4,977,089 |
| FARALLON CAPITAL MANAGEMENT LLC | $44.1M | 1,604,590 |
| Paradigm Biocapital Advisors LP | $42.7M | 1,553,748 |
| Commodore Capital LP | $38.9M | 1,415,000 |
| RA CAPITAL MANAGEMENT, L.P. | $28.0M | 1,020,410 |
| Jupiter Topco LLC | $23.4M | 849,309 |
| BlackRock, Inc. | $21.1M | 766,819 |
| Parkman Healthcare Partners LLC | $19.8M | 721,181 |
| VANGUARD CAPITAL MANAGEMENT LLC | $15.4M | 558,942 |
| Point72 Asset Management, L.P. | $12.7M | 460,593 |
Companies Similar to ASMB
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Cue Biopharma, Inc.
Editas Medicine, Inc.
Xilio Therapeutics, Inc.
MACROGENICS INC
Tango Therapeutics, Inc.
Zai Lab Ltd
Century Therapeutics, Inc.
Tarsus Pharmaceuticals, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ASMB on your watchlist
Track score changes the day ASSEMBLY BIOSCIENCES, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ASMB a good stock to buy?
13F Pro's AI-powered analysis of ASSEMBLY BIOSCIENCES, INC. (ASMB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ASMB are available on the ASMB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ASMB is classified as a small company.
Which hedge funds own ASMB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ASMB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ASSEMBLY BIOSCIENCES, INC.'s investment landscape.